Latrepirdine

Drug Profile

Latrepirdine

Alternative Names: BRN-0622478; Dimebolin; Dimebon; PF-01913539; PF-1913539

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Medivation
  • Class Antidementias; Indoles; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Butyrylcholinesterase inhibitors; Mitochondrial permeability transition pore modulators; Neuron stimulants; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Huntington's disease

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 17 Jan 2012 Pfizer terminates its global licence for latrepirdine
  • 17 Jan 2012 Discontinued - Phase-I for Alzheimer's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top